Chemotherapy is one of the main modalities in the treatment of cancer, but with the cost of unspecific killing of normal cells and considerable systemic toxicity. Encapsulation of the drug(s) in biodegradable nanoparticles (NPs) has the potential to reduce the side effects and simultaneously keep a high dose of the active drug in the tumor by utilizing the enhanced permeation and retention (EPR) effect, and also through active targeting of the NPs. We are collaborating with different partners who produce NPs, and have obtained promising data using poly(alkyl cyanoacrylate) (PACA) nanoparticles (produced by Sintef) in breast cancer PDX models. The project is performed in close collaboration with Prof Kirsten Sandvig, Department of Molecular Cell Biology, Institute for Cancer Research, and in a newly funded project (Cancer Society, 2019-21) we will actively target the PACA particles to the tumor cells.
Strategies to inhibit FGFR4 V550L-driven rhabdomyosarcoma
Br J Cancer (in press)
Cost-effectiveness of molecularly matched off-label therapies for end-stage cancer - the MetAction precision medicine study
Acta Oncol, 61 (8), 955-962
Corrigendum to "Cabazitaxel-loaded Poly(2-ethylbutyl cyanoacrylate) nanoparticles improve treatment efficacy in a patient derived breast cancer xenograft", [Journal of Control Release, 293 (2019) 183-192]
J Control Release, 349, 1